Viriom
Developing novel and affordable therapies against life threatening infections such as HIV and HBV.
Launch date
Market cap
-
Enterprise valuation
€8—12m (Dealroom.co estimates May 2016.)
Khimki Moscow Oblast (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | $3.0m | Convertible | |
* | €2.0m | Early VC | |
€2.0m | Grant | ||
$2.6m | Convertible | ||
$12.5m | Convertible | ||
| Total Funding | €20.4m | ||
Related Content
Recent News about Viriom
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.